BR112022013027A2 - Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn) - Google Patents

Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn)

Info

Publication number
BR112022013027A2
BR112022013027A2 BR112022013027A BR112022013027A BR112022013027A2 BR 112022013027 A2 BR112022013027 A2 BR 112022013027A2 BR 112022013027 A BR112022013027 A BR 112022013027A BR 112022013027 A BR112022013027 A BR 112022013027A BR 112022013027 A2 BR112022013027 A2 BR 112022013027A2
Authority
BR
Brazil
Prior art keywords
ald
amn
prevention
treatment
adrenomyeloeuropathy
Prior art date
Application number
BR112022013027A
Other languages
English (en)
Portuguese (pt)
Inventor
Kozarsky Karen
Guven-Ozkan Tugba
Tretiakova Anna
clark Sean
Original Assignee
Swanbio Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swanbio Therapeutics Ltd filed Critical Swanbio Therapeutics Ltd
Publication of BR112022013027A2 publication Critical patent/BR112022013027A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022013027A 2019-12-31 2020-12-31 Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn) BR112022013027A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962955667P 2019-12-31 2019-12-31
PCT/US2020/067664 WO2021138559A1 (en) 2019-12-31 2020-12-31 Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)

Publications (1)

Publication Number Publication Date
BR112022013027A2 true BR112022013027A2 (pt) 2022-09-06

Family

ID=76686949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013027A BR112022013027A2 (pt) 2019-12-31 2020-12-31 Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn)

Country Status (11)

Country Link
US (2) US11779655B2 (cg-RX-API-DMAC7.html)
EP (1) EP4085143B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023509443A (cg-RX-API-DMAC7.html)
KR (1) KR20220128632A (cg-RX-API-DMAC7.html)
CN (1) CN116096904A (cg-RX-API-DMAC7.html)
AU (1) AU2020416291A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013027A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166374A1 (cg-RX-API-DMAC7.html)
IL (1) IL294278A (cg-RX-API-DMAC7.html)
MX (1) MX2022008201A (cg-RX-API-DMAC7.html)
WO (1) WO2021138559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3228344A1 (en) * 2021-08-06 2023-02-09 Wuhan Neurophth Biotechnology Limited Company Composition and method for treating leber's hereditary optic neuropathy caused by nd4 mutation
US20240229067A9 (en) * 2022-05-12 2024-07-11 AAVnerGene Inc. Compositions and methods for recombinant parvovirus production
WO2023220502A1 (en) * 2022-05-12 2023-11-16 AAVnerGene Inc. Compositions and methods for recombinant parvovirus production
EP4536862A1 (en) * 2022-06-09 2025-04-16 Wisconsin Alumni Research Foundation Generation of next generation recombinant aav gene therapy vectors that adopt 3d conformation
AU2024315073A1 (en) * 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
AU2009273239B2 (en) * 2008-07-23 2015-07-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel regulatory elements
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
DK2717922T3 (en) * 2011-06-10 2019-01-07 Bluebird Bio Inc GENERATIVE VECTORS FOR ADDRENOLEUCODYSTROPHY AND ADDRENOMYELONE EUROPE
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
EP2940131B1 (en) * 2012-12-25 2019-02-20 Takara Bio Inc. Aav variant
WO2015153889A2 (en) * 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
EP3270960A4 (en) * 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
EP3285788B1 (en) * 2015-04-23 2024-12-18 University of Massachusetts Modulation of aav vector transgene expression
PL3370705T3 (pl) * 2015-11-05 2022-08-01 The General Hospital Corporation Dooponowe dostarczanie sekwencji kwasów nukleinowych do kodowania abcd1 w leczeniu adrenomieloneuropatii
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
WO2017137585A1 (en) * 2016-02-12 2017-08-17 Combigene Ab Vector
CN107287239B (zh) * 2016-04-11 2020-09-22 厦门继景生物技术有限责任公司 一种用于视网膜色素变性的基因治疗载体及药物
ES2982489T3 (es) * 2016-08-19 2024-10-16 Univ Florida Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios
CA3050690A1 (en) * 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosing and treating peroxisomal diseases
CN110650624A (zh) * 2017-03-10 2020-01-03 威斯康星州医药大学股份有限公司 用于视网膜疾病的核糖开关调节的基因治疗
US20200377887A1 (en) * 2017-09-22 2020-12-03 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
US12201657B2 (en) * 2017-10-18 2025-01-21 City Of Hope Adeno-associated virus compositions for restoring HBB gene function and methods of use thereof
GB201817470D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy

Also Published As

Publication number Publication date
US20240009326A1 (en) 2024-01-11
US20220175965A1 (en) 2022-06-09
EP4085143B1 (en) 2025-08-13
US20220362403A2 (en) 2022-11-17
US11779655B2 (en) 2023-10-10
WO2021138559A1 (en) 2021-07-08
AU2020416291A1 (en) 2022-07-21
CA3166374A1 (en) 2021-07-08
EP4085143A1 (en) 2022-11-09
KR20220128632A (ko) 2022-09-21
CN116096904A (zh) 2023-05-09
IL294278A (en) 2022-08-01
MX2022008201A (es) 2022-10-18
EP4085143A4 (en) 2024-02-28
JP2023509443A (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
MX2022008201A (es) Construcciones mejoradas de aav-abcd1 y su uso para su tratamiento o prevención de adrenoleucodistrofia (ald) y/o adrenomieloneuropatía (amn).
MX2022001328A (es) Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
PH12020500663A1 (en) Brm targeting compounds and associated methods of use
MY206825A (en) Pyridazinyl thiazolecarboxamide compound
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112018009645A2 (pt) composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
BR112021025676A2 (pt) Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
BR112015026258A2 (pt) composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112017010994A2 (pt) ?processo para o tingimento das fibras de queratina e composição cosmética?
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
MX2019008589A (es) Composicion de dieta para la prevencion y/o el tratamiento para la hiperplasia endometrial.
BR112021016783A2 (pt) Composições e métodos para tratar laminopatias
MX385860B (es) Peptido para usarse para reducir la necesidad de cirugía en pacientes que tienen hiperplasia prostática beningna.
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX2022005644A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
PH12021550122A1 (en) Solubilized apyrases, methods and use
BR112019024082A2 (pt) Métodos de tratamento para distonia cervical